首页>投融资

Upstream Bio

上市

This company profile has not been updated since April 2013, when Upstream Biosciences was dissolved.Upstream Biosciences, founded in 2004, was a biotechnology company, focused on discovering, developing and licensing genetic markers for cancer susceptibility and drug response. In July 2009, Upstream formed an independent committee of the Board to assess the strategic direction of the company; however, in April 2013, the company was dissolved.The company previously maintained a website at http://www.upstreambio.com/ but this was no longer available by December 2011.The company was based in Vancouver, Canada.In August 2009, Upstream was actively seeking licensors or acquirers for its antiparasitic drug discovery portfolio and cancer diagnostic platform.In January 2008, Upstream Biosciences formed a collaboration with the Combinatorial Chemistry Center of the Chemistry Department of Lomonosov Moscow State University (MSU) for the chemical synthesis of novel co

470180

基本信息

公司全称

Upstream Biosciences Inc
类型

免疫药物研发商
产业领域

药品研发/制造、医药研发/制造、化学药
公司人数

15~50人
地址

Clark Wilson LLP 800-885 West Georgia Street Vancouver British Columbia V6C3H1; CA;
联系电话

+1-800-539-0289
邮箱

info@upstreambio.com
成立时间

2004-01-01

投融资

2024-10-11

上市

2.55亿美元

未透露
2023-06-08

B轮

2亿美元

HBM Healthcare

Access Industries

Altshuler Shaham Group

Venrock Capital

TCG X

奥博资本

德诚资本

Omega Funds

Wellington Management

Enavate Sciences

Bain Capital

Samsara BioCapital
2022-06-02

A轮

2亿美元

Samsara BioCapital

Omega Funds

HBM Healthcare

TCG X

奥博资本

Access Industries

Maruho

Altshuler Shaham Group

德诚资本

Upstream Bio

基本信息

投融资

相关投融资企业